Mendus
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. They leverage their expertise in dendritic cell biology to develop advanced immunotherapies that are effective and safe.
Industries
Nr. of Employees
small (1-50)
Mendus
Västra Trädgårdsgatan 15, 111 53 Stockholm, Sweden
Patents
Products
Clinical-stage allogeneic dendritic cell-based immunotherapy candidates
Cell-based immunotherapy candidates developed from dendritic cell biology intended as maintenance therapies to reduce tumor recurrence and improve long-term outcomes; currently in clinical development including late-stage trial preparations.
Clinical-stage allogeneic dendritic cell-based immunotherapy candidates
Cell-based immunotherapy candidates developed from dendritic cell biology intended as maintenance therapies to reduce tumor recurrence and improve long-term outcomes; currently in clinical development including late-stage trial preparations.
Services
Collaborative R&D and clinical development partnerships to advance cell-based immunotherapy candidates from preclinical research into clinical trials.
Collaborative R&D and clinical development partnerships to advance cell-based immunotherapy candidates from preclinical research into clinical trials.
Expertise Areas
- Cancer immunotherapy development
- Dendritic cell-based therapy
- Clinical trial management for oncology
- Immune monitoring and biomarker-driven development
Key Technologies
- Dendritic cell-based immunotherapy
- Allogeneic (off-the-shelf) cell therapy
- Immune monitoring and biomarker assays
- Translational immunology
News & Updates
Mendus presents data at ASH 2024 demonstrating durable survival of AML patients treated with Vididencel.
Mendus presents successful induction of tumor-directed immune responses in high-risk ovarian cancer at ASCO 2025.
Mendus presents data on AML and solid tumor programs at CIMT 2025.
Mendus appoints Dr. Tariq Mughal as Chief Medical Officer to strengthen late-stage clinical development.
Mendus publishes interim financial report for Q1 2025.
Mendus presents data at ASH 2024 demonstrating durable survival of AML patients treated with Vididencel.
Mendus presents successful induction of tumor-directed immune responses in high-risk ovarian cancer at ASCO 2025.
Mendus presents data on AML and solid tumor programs at CIMT 2025.
Mendus appoints Dr. Tariq Mughal as Chief Medical Officer to strengthen late-stage clinical development.
Mendus publishes interim financial report for Q1 2025.